Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Pooled it
- Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.Frontiers in oncology · 2020Pooled it
- Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.Blood advances · 2025Trial
- Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.Annals of hematology · 2025Trial
- Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.Blood advances · 2021Trial
- Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Eprenetapopt (APR-246) and Azacitidine inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.Blood advances · 2020Trial
- Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.International journal of cancer · 2019Trial
- Lactylation modification regulates acute myeloid leukemia pathogenesis and immune microenvironment.Discover oncology · 2025Article
- Review
- Article
- Interplay of oxidative stress, cellular communication and signaling pathways in cancer.Cell communication and signaling : CCS · 2024Review
- Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches.Frontiers in oncology · 2024Review
- A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood cancer discovery · 2023Article
- Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review.Cureus · 2023Review
- What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.Cancers · 2023Review
- Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia.Biomedicines · 2023Review
- Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.Journal of geriatric oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 4 institutions in 1 country.
Charles F CraddockCentre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom. Charles.Craddock@uhb.nhs.uk paresh.vyas@imm.ox.ac.uk.
Aimee E HoultonCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
Lynn Swun QuekMRC Molecular Haematology Unit and Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Paul FergusonCentre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Emma GbandiCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
Corran RobertsCentre for Statistics in Medicine, Oxford, United Kingdom.
Marlen MetznerMRC Molecular Haematology Unit and Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Natalia Garcia-MartinMRC Molecular Haematology Unit and Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Alison KennedyMRC Molecular Haematology Unit and Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Angela HamblinMRC Molecular Haematology Unit and Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Manoj RaghavanCentre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Sandeep NagraCentre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Louise DudleyCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
Keith WheatleyCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
Mary Frances McMullinDepartment of Haematology, Queen's University, Belfast, United Kingdom.
Srinivas P PillaiUniversity Hospitals of North Midlands, Stoke on Trent, United Kingdom.
Richard J KellyLeeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Shamyla SiddiqueCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
Michael DennisThe Christie NHS Foundation Trust, Manchester, United Kingdom.
Jamie D CavenaghDepartment of Haemato-Oncology, St Bartholomew's Hospital, Bart's Health NHS Trust, London, United Kingdom.
Paresh VyasMRC Molecular Haematology Unit and Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom. Charles.Craddock@uhb.nhs.uk paresh.vyas@imm.ox.ac.uk.
University of Birmingham · GBQueen Elizabeth Hospital Birmingham · GBLeeds Teaching Hospitals NHS Trust · GBThe Christie NHS Foundation Trust · GB
Funding
Cancer Research UK 15958Cancer Research UK 16895Medical Research Council G1000729Medical Research Council MC_UU_12009/11Medical Research Council MR/L008963/1
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Disease-Free SurvivalDrug Administration ScheduleFemaleHistone Deacetylase InhibitorsHumansHydroxamic AcidsIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleAzacitidineCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Histone Deacetylase InhibitorsHydroxamic AcidsIDH1 protein, humanIsocitrate DehydrogenaseTP53 protein, humanTumor Suppressor Protein p53Vorinostat
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.